Cargando…
The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma
This study aimed to investigate the activity of arsenic trioxide (As(2)O(3)) combined with ascorbic acid, ifosfamide, and prednisone chemotherapy in patients with repeatedly relapsed and refractory multiple myeloma (MM). Here, we retrospectively analyzed medical data of 30 MM patients showing progre...
Autores principales: | Li, Xin, Sun, Wan-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399549/ https://www.ncbi.nlm.nih.gov/pubmed/25914547 http://dx.doi.org/10.2147/OTT.S81022 |
Ejemplares similares
-
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review
por: He, Xuepeng, et al.
Publicado: (2014) -
Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
por: Bolaman, Ali Zahit, et al.
Publicado: (2021) -
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022) -
Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
por: Shi, Haotian, et al.
Publicado: (2023) -
Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia
por: Yedjou, Clement, et al.
Publicado: (2009)